Antibody response to Cryptococcus neoformans proteins in rodents and humans

Infection and Immunity

Volumn 67, Issue 5, 1999, Pages 2218-2224

  Chen, Lin Chi ^a   Goldman, David L ^a   Doering, Tamara L ^b   Pirofski, Liise Anne ^a   Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUNGAL PROTEIN; FUNGUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; VACCINATION;

EID: 0032921890     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.5.2218-2224.1999     Document Type: Article

References (41)

1. Atkinson, A. J., and J. E. Bennett. 1968. Experience with a new skin test antigen prepared from Cryptococcus neoformans. Am. Rev. Resp. Dis. 97: 637-643.
2. Baker, R. D. 1976. The primary pulmonary lymph node complex of cryptococcosis. Am. J. Clin. Pathol. 65:83-92.
3. Bindschadler, D. D., and J. E. Bennett. 1968. Serology of human cryptococcosis. Ann. Intern. Med. 69:45-52.
4. Casadevall, A. 1995. Antibody immunity and invasive fungal infections. Infect. Immun. 63:4211-4218.
5. Casadevall, A., A. Cassone, F. Bistoni, J. E. Cutler, W. Magliani, J. W. Murphy, L. Polonelli, and L. Romani. 1998. Antibody and/or cell-mediated immunity, protective mechanisms in fungal disease: an ongoing dilemma or an unnecessary dispute? Med. Mycol. 36:95-105.
6. Casadevall, A., J. Mukherjee, S. J. N. Devi, R. Schneerson, J. B. Robbins, and M. D. Scharff. 1992. Antibodies elicited by a Cryptococcus neoformans glucuronoxylomannan-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J. Infect. Dis. 65:1086-1093.
7. Currie, B. P., L. F. Freundlich, and A. Casadevall. 1994. Restriction fragment length polymorphism analysis of Cryptococcus neoformans isolates from environmental (pigeon excreta) and clinical isolates in New York City. J. Clin. Microbiol. 32:1188-1192.
8. Deepe, G. S., Jr. 1997. Prospects for the development of fungal vaccines. Clin. Microbiol. Rev. 10:585-596.
9. - individuals. Clin. Exp. Immunol. 99:425-432.
10. Devi, S. J. N. 1996. Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. Vaccine 14:841-842.
11. Devi, S. J. N., P. G. Reddy, C. A. Lyman, T. J. Walsh, C. E. Frasch, and A. C. Bush. 1996. Immunohistochemical properties of a polysaccharide antigen of Trichosporon beigelii that cross-reacts with the capsular polysaccharide of Ciyptococcus neoformans. Immunol. Infect. Dis. 6:87-92.
12. Diamond, R. D., and J. E. Bennett. 1974. Prognostic factors in cryptococcal meningitis. Ann. Intern. Med. 80:175-181.
13. Dromer, F., P. Aucouturier, J.-P. Clauvel, G. Saimot, and P. Yeni. 1988. Cryptococcus neoformans antibody levels in patients with AIDS. Scand. J. Infect. Dis. 20:283-285.
14. Dromer, F., D. W. Denning, D. A. Stevens, A. Nobel, and J. R. Hamilton. 1995. Anti-Cryptococcus neoformans antibodies during cryptococcosis in patients with the acquired immunodeficiency syndrome. Serodiagn. Immunother. Infect. Dis. 7:181-188.
15. Dromer, F., P. Yeni, and J. Charreire. 1988. Genetic control of the humoral response to cryptococcal capsular polysaccharide in mice. Immunogenetics 28:417-424.
16. Goldman, D., S. C. Lee, and A. Casadevall. 1994. Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect. Immun. 62:4755-4761.
17. Goldman, D. L., B. C. Fries, S. P. Franzot, L. Montella, and A. Casadevall. 1998. Phenotypic switching in the human pathogenic fungus Cryptococcus neoformans is associated with changes in virulence and pulmonary inflammatory response in rodents. Proc. Natl. Acad. Sci. USA 95:14967-14972.
18. Graybill, J. R. 1974. Cell-mediated immunity in cryptococcosis. Cell. Immunol. 14:12-21.
19. Hamilton, A. J., M. A. Bartholomew, J. Figueroa, L. E. Fenelon, and R., J. Hay. 1991. Production of species-specific murine monoclonal antibodies against Cryptococcus neoformans which recognize a noncapsular antigen. J. Clin. Microbiol. 29:980-984.
20. Hamilton, A. J., J. I. Figueroa, L. Jeavons, and R. A. Seaton. 1997. Recognition of cytoplasmic yeast antigens of Cryptococcus neoformans and Cryptococcus neoformans var. gattii by immune human sera. FEMS Immunol. Med. Microbiol. 17:111-119.
21. Hamilton, A. J., L. Jeavons, P. Hobby, and R. J. Hay. 1992. A 34- to 38-kilodaltoan Cryptococcus neoformans glycoprotein produced as an exoantigen bearing a glycosylated species-specific epitope. Infect. Immun. 60:143-149.
22. Houpt, D. C., G. S. T. Pfrommer, B. J. Young, T. A. Larson, and T. R. Kozel. 1994. Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan. Infect. Immun. 62:3857-2864.
23. Kakeya, H., H. Udono, N. Ikuno, Y. Yamamoto, K. Mitsutake, T. Miyazaki, K. Tomono, H. Koga, T. Tashiro, E. Nakayama, and S. Kohno. 1997. A 77-kilodalton protein of Cryptococcus neoformans a member of the heat shock protein 70 family, is a major antigen detected in the sera of mice with pulmonary cryptococcosis. Infect. Immun. 65:1653-1658.
24. Keller, R. G., G. S. Pfrommer, and T. R Kozel. 1994. Occurrences, specificities, and functions of ubiquitous antibodies in human serum that are reactive with the Cryptococcus neoformans cell wall. Infect. Immun. 62:215-220.
25. Koch, G. G., I. A. Amara, G. W. Davis, and D. B. Gillings. 1982. A review of some statistical methods for covariance analysis of categorical data. Biometrics 38:563-595.
26. Levitz, S. M. 1991. The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev. Infect. Dis. 13:1163-1169.
27. Littman, M. L. 1959. Cryptococcosis (torulosis). Am. J. Med. 27:976-998.
28. Littman, M. L. 1968. Cryptococcosis: current status. Am. J. Med. 45:922-932.
29. Lyashcbenko, K., T. Colangeli, M. Houde, H. A. Jahdali, D. Menzies, and M. L. Gennaro. 1998. Heterogeneous antibody responses in tuberculosis. Infect. Immun. 66:3936-3940.
30. Lyashchenko, K., J. M. Pollock, R. Colangeli, and M. L. Gennaro. 1998. Diversity of antigen recognition by serum antibodies in experimental bovine tuberculosis. Infect. Immun. 66:5344-5349.
31. Mitchell, T. G., and J. R. Perfect 1995. Cryptococcosis in the era of AIDS -100 years after the discovery of Cryptococcus neoformans. Clin. Microbiol. Rev. 8:515-548.
32. Mohr, J. A., H. G. Muchmore, F. G. Felton, E. R. Rhoades, and B. A. McKwon. 1970. The effect of cryptococcin on leukocytic migration. J. Infect. Dis. 122:454-458.
33. Muchmore, H. G., F. G. Felton, S. B. Salvin, and E. R. Rhoades. 1968. Delayed hypersensitivity to cryptococcin in man. Sabouraudia 6:285-288.
34. Murphy, J. W. 1992. Cryptococcal immunity and immunostimulation. Adv. Exp. Med. Biol. 319:225-230.
35. Perfect, J. R., D. T. Durack, and H. A. Gallis. 1983. Cryptococcemia. Medicine 62:98-109.
36. Perfect, J. R., S. D. R. Lang, and D. T. Durack. 1980. Chronic cryptococcal meningitis. Am. J. Pathol. 191:177-193.
37. Pirofski, L., and A. Casadevall. 1996. Antibody immunity to Cryptococcus neoformans: paradigm for antibody immunity to the fungi? Zentbl. Bakteriol. 284:475-495.
38. Schimpff, S. C., and J. E. Bennett. 1975. Abnormalities in cell-mediated immunity in patients with Cryptococcus neoformans infection. J. Allergy Clin. Immunol. 55:430-441.
39. Solomkin, J. S., E. L. Mills, G. S. Giebink, R. D. Nelson, R. Simmons, and P. G. Quie. 1978. Phagocytosis of Candida albicans by human leukocytes: opsonic requirements. J. Infect. Dis. 137:30-37.
40. Spitzer, E. D, and S. G. Spitzer. 1992. Use of a dispersed repetitive DNA element to distinguish clinical isolates of Cryptococcus neoformans. J. Clin. Microbiol. 30:1094-1097.
41. Zhang, H., Z. Zhong, and L. Pirofski. 1997. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody. Infect. Immun. 65:1158-1164.